It is expected that arsenite will sensitise tumour cells, which are defective in the PRDX1 function, and that increasing the doses of arsenite could have additional benefits by triggering the degradation of GLUT3, thereby starving the cells of glucose. The gene discussed is SLC2A3; the disease is neoplasm.